CanSino Biologics (HKSE:06185) Cash, Cash Equivalents, Marketable Securities : HK$4,361.3 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics Cash, Cash Equivalents, Marketable Securities?

CanSino Biologics's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 (HK$4,657.65 Mil) to Dec. 2023 (HK$4,506.33 Mil) but then stayed the same from Dec. 2023 (HK$4,506.33 Mil) to Mar. 2024 (HK$4,361.27 Mil).

CanSino Biologics's annual cash, cash equivalents, marketable securities declined from Dec. 2021 (HK$9,529.91 Mil) to Dec. 2022 (HK$6,640.87 Mil) and declined from Dec. 2022 (HK$6,640.87 Mil) to Dec. 2023 (HK$4,506.33 Mil).

CanSino Biologics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for CanSino Biologics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Cash, Cash Equivalents, Marketable Securities Chart

CanSino Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

839.90

6,061.91

9,529.91

6,640.87

4,506.33

CanSino Biologics Quarterly Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial													-	4,765.01	4,657.65	4,506.33	4,361.27

CanSino Biologics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

CanSino Biologics (HKSE:06185) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

CanSino Biologics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

CanSino Biologics (HKSE:06185) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » Cash, Cash Equivalents, Marketable Securities

Traded in Other Exchanges

CASBF:USA CJH:Germany 688185:China

Address

185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN

Website

https://www.cansinotech.com

CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.

Executives

The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.
Citigroup Inc.
The Goldman Sachs Group, Inc.	2201 Interest of corporation controlled by you
Blackrock, Inc.	2201 Interest of corporation controlled by you
Mao Helen Huihua	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p.	2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p.	2201 Interest of corporation controlled by you
Qm29 Limited	2101 Beneficial owner
Qiu Dongxu	2501 Other
Yu Xuefeng	2501 Other
Zhu Tao
Chao Shou Bai	2202 Interest of your spouse
Orbimed Capital Llc	2102 Investment manager

CanSino Biologics (HKSE:06185) Headlines

No Headlines